Episode Details

Host Jessica Seidelman, MD and guests Kerry LaPlante, Pharm.D., FCCP, FIDSA, FIDP, and Julie Ann Justo, Pharm.D. conclude this 3-part series with discussions on pipeline innovations and adjunctive strategies for treating challenging prosthetic joint infections. Topics include local antibiotic administration, phage therapy, and immunotherapy. Thanks to Osteal Therapeutics for sponsoring this episode. For more information about VT-X7, including the APEX clinical trials results, please visit Ostealtx.com

Listen to Breakpoints: The SIDP Podcast

References:

“Antibiotic Therapy for 6 or 12 Weeks for Prosthetic Joint Infection” PMID 34042388

“NDM-9 resistance to taniborbactam” PMID 36796395

“Wide dissemination of Gram-negative bacteria producing the taniborbactam-resistant NDM-9 variant: a One Health concern” PMID 37394537

IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections https://www.idsociety.org/practice-guideline/amr-guidance/

“Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety” PMID 30648126

“Corynebacterium striatum Prosthetic Joint Infection Successfully Treated with Long-Term Dalbavancin”